DURHAM, N.C.--(BUSINESS WIRE)--Jan. 30, 2006--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced plans to initiate a Phase 3 program to advance denufosol tetrasodium for the treatment of cystic fibrosis (CF). This follows the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA).